DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Orchid Pharma Limited — Monitoring Agency Report

NSE 2 hrs ago·14 Aug 2026, 1:21 pm

Orchid Pharma

Orchid Pharma has released its monitoring agency report for the first quarter of financial year 2026-27. This document is a standard regulatory filing that provides an overview of the company's performance and compliance status during the specified period.

For investors, this report is a key source of information. It offers a snapshot of the company's operational health and helps track progress against previous quarters. While it does not contain detailed financial results, it is a critical document for assessing the company's adherence to regulatory standards and ongoing business activities.

Investors should watch for any specific observations or concerns raised by the monitoring agency. These details can provide valuable context regarding the company's standing and future outlook.